ACTRN12615001126505尚未招募1 期
A pilot study to examine the persistence and immunogenicity of Plasmodium falciparum 7G8 blood stage parasites following commencement of doxycycline chemoprophylaxis in healthy male adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- Male
入选标准
- •1.Volunteers will be males, aged 18-50 years of age who do not live alone for the duration of the study.
- •2.Volunteers must have a BMI within the range of 18-30.
- •3.Volunteers must understand the procedures involved and agree to participate in the study by giving fully informed, written consent.
- •4.Be contactable and available for the duration of their study schedule (maximum of 3 months)
- •5.Volunteers must be non-smokers or smoke less than or equal to 5 cigarettes/day and in good health, as assessed during pre-study medical examination and by review of screening results
- •6.Good peripheral venous access
排除标准
- •1.Has increased cardiovascular disease risk (defined as greater than 10%, 5 yr risk) as determined by the method of Gaziano et al 2008. Risk factors include: sex, age, systolic blood pressure, smoking status, body mass index (BMI, kg/mm2), and reported diabetes status and blood pressure.
- •2.History of splenectomy
- •3.History of severe allergic reaction, anaphylaxis or convulsion following any vaccination, infusion or treatment with anti-malarial drugs artemether and/or lumefantrine.
- •4.Presence of current or suspected chronic diseases such as cardiac or autoimmune disease (HIV or other immunodeficiencies), insulin dependent diabetes, progressive neurological disease, severe malnutrition, acute or progressive hepatic disease, acute or progressive renal disease, psoriasis, rheumatoid arthritis, asthma, epilepsy, obsessive compulsive disorder, myasthenia gravis, skin carcinoma excluding non-spreadable skin cancers such as basal cell and squamous cell carcinoma.
- •5.Known inherited genetic anomaly (known as cytogenic disorders) eg Down’s syndrome.
- •6.Individuals wishing to donate blood to the Australian Red Cross Blood Service during the study or within 12 months of administration of the malaria inoculum.
- •7.The volunteer has a diagnosis of schizophrenia, bi-polar disease, severe depression or other severe (disabling) chronic psychiatric disorder. Participants who are receiving a single anti-depressant drug and are stable for at least 3 months prior to enrollment without decompensating may be allowed to enroll in the study at the investigator’s discretion.
- •8.Has been hospitalised in the past 5 years prior to enrolment for psychiatric illness, history of suicide attempt or confinement for danger to self or others.
- •9.Known pre-existing prolongation of the QTc interval. Family history of congenital prolongation of the QTc interval on electrocardiograms or of sudden death or any other clinical conditions known to prolong the QTc interval eg volunteers with a history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.
- •10.Recent or current therapy with antibiotic or drug with potential antimalarial activity (tetracycline, azithromycin, clindamycin, hydroxychloroquine etc).
- •11.Known allergy to any medicine containing doxycycline, other tetracyclines, or any other ingredients contained within the medicine.
- •12.Recent or current therapy with medicine containing vitamin A or retinoids such as isotretinoin (eg Absorica, Accutane, Amnesteem, Claravis, Sotret) and etretinate (eg Tegison).
- •13.Concomitant use of any drug which is metabolized by the cytochrome enzyme CYP2D6 (eg flecainide, metoprolol, imipramine, amitriptyline, clomipramine) OR drugs that are known to prolong the QTc interval e.g. antiarrhythmics of classes IA and III, neuroleptics, antidepressant agents, certain antibiotics (including some agents of the following classes: macrolides, fluoroquinolones, imidazole and triazole antifungal agents), certain non-sedating antihistamines (terfenadine, astemizole), cisapride.
- •14.Use of corticosteroids, anti-inflammatory drugs, any immunomodulators or anticoagulants. Currently receiving or have previously received immunosuppressive therapy, including systemic steroids including ACTH or inhaled steroids in dosages which are associated with hypothalamic-pituitary axis suppression such as 1mg/kg/day or prednisone or its equivalent or chronic use of inhaled high potency cortic
研究者
相似试验
招募中
不适用
Acupuncture and reproductive health outcomes: building evidence in an integrated care setting.Immune System HealthReproductive HealthReproductive Health and Childbirth - Fertility including in vitro fertilisationInflammatory and Immune System - Normal development and function of the immune systemAlternative and Complementary Medicine - Other alternative and complementary medicineACTRN12609000923268niversity of Western Sydney40
招募中
不适用
A pilot study to investigate the immunological regulation of preeclampsiaO14Pre-eclampsiaDRKS00025864Carl von Ossietzky Universität Oldenburg/Klinikum Oldenburg; Universitätsklinik für Gynäkologie und Geburtshilfe200
进行中（未招募）
不适用
Immunogenicity and safety study of booster dose of GSK Biologicals’ IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) vaccine.Booster immunisation of healthy children in the second year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.EUCTR2012-003324-20-Outside-EU/EEAGlaxoSmithKline Biologicals831
进行中（未招募）
1 期
A study on the anti-inflammatory effects of azithromycin in tuberculosisPulmonary tuberculosisEUCTR2017-001929-40-NLniversity Medical Center Groningen24
招募中
2 期
A prospective, randomized pilot study of the immunomodulatory effects of azithromycin in adults with pulmonary tuberculosisTBTuberculosisNL-OMON47928niversitair Medisch Centrum Groningen24